TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26269365

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage consumption (≥1 serving per day)
Number of subjects: 240508

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage consumption (dose-response analysis)
Number of subjects: 240508
Study: 26269366

Group type: EXPERIMENTAL
Intervention: Elevated total dietary fiber intake
Number of subjects: 57774
Study: 26269367

Group type: EXPERIMENTAL
Intervention: Maternal folate intake
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Cord blood folate concentration
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Fetal MTHFR 677TT genotype
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: UMFA detection
Number of subjects: 368
Study: 26270946

Group type: EXPERIMENTAL
Intervention: Pharmacist care intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 100
Study: 26271642

Group type: EXPERIMENTAL
Intervention: Symptom severity (measured by adult EoE activity index)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Endoscopic findings
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Histological findings
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Symptom severity, endoscopic and histological findings combined
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 98
Study: 26271944

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with nevirapine (400 mg once daily) and abacavir/lamivudine (600/300 mg once daily)
Number of subjects: 10
Study: 26272346

Group type: EXPERIMENTAL
Intervention: Programme cantonal Diabète (PcD)
Number of subjects: 0
Study: 26272385

Group type: EXPERIMENTAL
Intervention: CoaguChek POCT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laboratory-based coagulation assays (prothrombin time, activated partial thromboplastin time, anti-Xa test, Hemoclot)
Number of subjects: 60
Study: 26272656

Group type: EXPERIMENTAL
Intervention: SNPs at the PITX2 locus (rs6843082_G)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: SNPs at the PITX2 locus (rs2200733_T)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: SNPs at the ZFHX3 locus (rs2106261_A)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: SNPs at the KCNN3 locus (rs13376333_T)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Top AF-associated SNPs
Number of subjects: 1068
Study: 26272693

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 255
Study: 26273092

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 7046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7046
Study: 26274928

Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HMGB1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S100A12
Number of subjects: 60

Group type: COMPARATOR
Intervention: esRAGE
Number of subjects: 60

Group type: COMPARATOR
Intervention: AGEs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sRAGE, esRAGE, S100A12, AGEs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sRAGE, HMGB1, S100A12
Number of subjects: 60
Study: 26275071

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 600
Study: 26275228

Group type: EXPERIMENTAL
Intervention: Protocol 1 (genetic testing for Fabry disease)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Protocol 2 (stent retrievers effectiveness evaluation)
Number of subjects: 35
Study: 26275293

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 34
Study: 26275339

Group type: EXPERIMENTAL
Intervention: HA DNA-IIV3
Number of subjects: 111

Group type: COMPARATOR
Intervention: PBS-IIV3
Number of subjects: 111

Group type: COMPARATOR
Intervention: IIV3-IIV3
Number of subjects: 111
Study: 26275521

Group type: EXPERIMENTAL
Intervention: Intraoperative hemodynamic monitoring (heart rate, mean arterial pressure, central venous pressure, cardiac index)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinary NGAL at the conclusion of surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cytokines (PTX3, IL1-RA, MCP, ST-2, IL-10)
Number of subjects: 40
Study: 26277428

Group type: EXPERIMENTAL
Intervention: Dementia Care Manager (DCM) curriculum
Number of subjects: 38
Study: 26277485

Group type: COMPARATOR
Intervention: Upper trapezius deformation during scapular elevation (superficial section)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Upper trapezius deformation after loaded arm abduction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Engagement of deep section of upper trapezius during scapular elevation task
Number of subjects: 36
Study: 26278063

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 26278654

Group type: EXPERIMENTAL
Intervention: PC needle (novel reverse bevel needle)
Number of subjects: 75

Group type: COMPARATOR
Intervention: QC needle (19-gauge Tru-cut biopsy needle)
Number of subjects: 75
Study: 26279673

Group type: EXPERIMENTAL
Intervention: Open Abdomen procedures
Number of subjects: 0
Study: 26279682

Group type: EXPERIMENTAL
Intervention: Foot orthoses only (FOO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Foot orthoses and eccentric exercise (FOE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham foot orthoses only (FOS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (FOO, FOE, FOS)
Number of subjects: 60
Study: 26280080

Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery
Number of subjects: 53
Study: 26280447

Group type: EXPERIMENTAL
Intervention: LCZ696 (Valsartan/Sacubitril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current medications (ACE inhibitors or angiotensin receptor antagonists)
Number of subjects: 0
Study: 26281907

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg/day for 21 days
Number of subjects: 53
Study: 26282191

Group type: EXPERIMENTAL
Intervention: ICD generator replacement
Number of subjects: 800
Study: 26282537

Group type: EXPERIMENTAL
Intervention: Diagnostic methods (microscopic techniques, rapid diagnostic tests, stool culture, polymerase chain reaction) for detecting bacterial and parasitic pathogens.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Clinical treatment offered to all infected participants.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Development of patient-centred clinical algorithms.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Comparison of different diagnostic methods.
Number of subjects: 2000
Study: 26282634

Group type: EXPERIMENTAL
Intervention: High doses of methotrexate and cytarabine followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT). Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine.
Number of subjects: 38
Study: 26283632

Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna™)
Number of subjects: 10
Study: 26283670

Group type: EXPERIMENTAL
Intervention: Azithromycin (1.5 g for 5 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single oral dose)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 90
Study: 26283709

Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) measured at hospital discharge
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) quartile Q1 (slowest)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 4 m gait speed (4MGS) quartile Q1 (slowest) in patients aged 65 or over
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Multivariate model incorporating 4MGS and other factors
Number of subjects: 213
Study: 26283710

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 3464
Study: 26284164

Group type: EXPERIMENTAL
Intervention: Tempo-pace synchronized audio-devices with personalized music playlists + usual-care
Number of subjects: 34

Group type: COMPARATOR
Intervention: No music usual-care control
Number of subjects: 34
Study: 26284168

Group type: EXPERIMENTAL
Intervention: Runners (LDR, SDR)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Runners (LDR)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Swimmers (SDS, LDS)
Number of subjects: 445
Study: 26284689

Group type: EXPERIMENTAL
Intervention: Text message prompts to a mobile survey assessing activity, self-worth, and self-efficacy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometer
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Participant feedback on survey usability
Number of subjects: 9
Study: 26284823

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/day for 21/28 days
Number of subjects: 17
Study: 26284932

Group type: EXPERIMENTAL
Intervention: Methylphenidate (osmotic-release oral system)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-medicated respondents
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Respondents (medicated)
Number of subjects: 25
Study: 26285132

Group type: EXPERIMENTAL
Intervention: GTF2I allelic variations (specifically the single-nucleotide polymorphism rs2527367)
Number of subjects: 260
Study: 26285741

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (1 MAC)
Number of subjects: 133
Study: 26285768

Group type: EXPERIMENTAL
Intervention: Tamoxifen (120 mg PO twice daily) and bortezomib (1.3 mg/m2 IV on specified days) per 6-week cycles
Number of subjects: 42
Study: 26286026

Group type: EXPERIMENTAL
Intervention: Areca nut (AN) chewing
Number of subjects: 2700
Study: 26286255

Group type: EXPERIMENTAL
Intervention: Early risk-reducing salpingectomy (RRS) with delayed oophorectomy (RRO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard risk-reducing salpingo-oophorectomy (RRSO)
Number of subjects: 0
Study: 26286385

Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBST)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physiologic measures (maximal voluntary contraction)
Number of subjects: 53
Study: 26286450

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus ribavirin
Number of subjects: 236
Study: 26286544

Group type: EXPERIMENTAL
Intervention: Balloon-mounted stent
Number of subjects: 300

Group type: COMPARATOR
Intervention: Balloon plus self-expanding stent
Number of subjects: 300
Study: 26286816

Group type: EXPERIMENTAL
Intervention: Hydromorphone analgesia
Number of subjects: 0
Study: 26287849

Group type: EXPERIMENTAL
Intervention: vemurafenib in non-small-cell lung cancer
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: vemurafenib in Erdheim-Chester disease or Langerhans'-cell histiocytosis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: vemurafenib and cetuximab in colorectal cancer
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: vemurafenib in other cancers (pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, clear-cell sarcoma)
Number of subjects: 122
Study: 26288246

Group type: EXPERIMENTAL
Intervention: Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks
Number of subjects: 453
Study: 26288277

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via single colonoscopic administration
Number of subjects: 7
Study: 26288390

Group type: EXPERIMENTAL
Intervention: Weight percentile less than 10% during the year of enrollment
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: P. aeruginosa positive during the year of enrollment
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Crackles or wheeze during the year of enrollment
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Mother's education of high school or less
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Mother smoked during pregnancy
Number of subjects: 484
Study: 26290644

Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Both BOC and TVR
Number of subjects: 1057
Study: 26291023

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1
Study: 26291296

Group type: EXPERIMENTAL
Intervention: Scaling and root planing for patients with periodontitis (PD ≥4 to <7 mm)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α agents in patients with AS
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 168
Study: 26291753

Group type: EXPERIMENTAL
Intervention: ACOS criteria fulfilled (125 patients)
Number of subjects: 831

Group type: COMPARATOR
Intervention: Non-ACOS COPD patients
Number of subjects: 831
Study: 26291916

Group type: EXPERIMENTAL
Intervention: Health insurance outreach HIT tools implemented in CHCs
Number of subjects: 34867

Group type: COMPARATOR
Intervention: Matched control sites (no intervention)
Number of subjects: 34867
Study: 26292027

Group type: EXPERIMENTAL
Intervention: DNA/Ad vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: AdCA vaccine
Number of subjects: 15
Study: 26292221

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg (Cohort 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg (Cohort 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 12
Study: 26292257

Group type: EXPERIMENTAL
Intervention: P. falciparum pre-erythrocytic antigens (21 identified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBMC from RAS-immunized volunteers
Number of subjects: 0
Study: 26292583

Group type: EXPERIMENTAL
Intervention: XPF cap (barium sulfate/bismuth oxide layered cap)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ambient control
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Outside left
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Outside center
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Outside right
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inside left vs Outside left
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inside center vs Outside center
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Outside left vs Outside right
Number of subjects: 11
Study: 26293153

Group type: EXPERIMENTAL
Intervention: Elder-friendly Approaches to the Surgical Environment (EASE) interventions
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: EASE interventions
Number of subjects: 560
Study: 26293470

Group type: EXPERIMENTAL
Intervention: Automated electronic reminders for earlier switching from i.v. to p.o. antibiotics
Number of subjects: 22863

Group type: COMPARATOR
Intervention: No reminders (control group)
Number of subjects: 22863
Study: 26293568

Group type: EXPERIMENTAL
Intervention: SmartCare services with remote monitoring and health care services in addition to existing treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing outpatient treatments (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SmartCare services (intervention group).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing treatment (control group).
Number of subjects: 0
Study: 26293760

Group type: EXPERIMENTAL
Intervention: Initial LVEF <0.30
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline LVEF ≥0.30 and LVEDD <6.0 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LVEF at study entry
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Major cardiovascular events (death, transplantation, or LV assist device)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Race (black)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LVEDD ≥6.0 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presentation after 6 weeks post-partum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LVEF recovery
Number of subjects: 100
Study: 26294723

Group type: EXPERIMENTAL
Intervention: Pentostatin plus cyclophosphamide with ofatumumab
Number of subjects: 0
Study: 26296092

Group type: EXPERIMENTAL
Intervention: CC-486 (300mg once-daily for 14 or 21 days per 28-day cycle)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CC-486 (200mg twice-daily for 14 or 21 days per 28-day cycle)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CC-486 (200mg twice-daily for 21 days per 28-day cycle)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CC-486 (300mg once-daily for 21 days per 28-day cycle)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CC-486 (extended dosing)
Number of subjects: 59
Study: 26296295

Group type: EXPERIMENTAL
Intervention: Afatinib 40mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Afatinib 50mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Afatinib and paclitaxel combination
Number of subjects: 16
Study: 26296371

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) treatment of the prostate
Number of subjects: 16
Study: 26296473

Group type: EXPERIMENTAL
Intervention: Detection of anti-mPLA2R1 autoantibodies
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: rbPLA2R1 ELISA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: mPLA2R1 ELISA
Number of subjects: 41
Study: 26296952

Group type: EXPERIMENTAL
Intervention: RRx-001 (10 mg/m(2), 16·7 mg/m(2), 24·6 mg/m(2), 33 mg/m(2), 55 mg/m(2), 83 mg/m(2))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: RRx-001 (16·7 mg/m(2))
Number of subjects: 25
Study: 26297144

Group type: EXPERIMENTAL
Intervention: Standardized mobilization protocol before, 6 and 24 h after surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standing position at 6 h after surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standing position at 24 h after surgery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Supine position at 24 h after surgery
Number of subjects: 23
Study: 26297176

Group type: EXPERIMENTAL
Intervention: GM-CSF, rituximab, fludarabine, and cyclophosphamide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GM-CSF, rituximab, fludarabine, and mitoxantrone
Number of subjects: 15
Study: 26297222

Group type: EXPERIMENTAL
Intervention: Usual care plus Interactive Cholesterol Advisory Tool (first 8 weeks)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study: 26297810

Group type: EXPERIMENTAL
Intervention: Unsupervised home sleep apnea test combined with transcutaneous partial pressure of carbon dioxide/oxygen saturation by pulse oximetry monitoring
Number of subjects: 81
Study: 26299218

Group type: EXPERIMENTAL
Intervention: Standard demographic, clinical, and echocardiographic variables collection
Number of subjects: 2750

Group type: EXPERIMENTAL
Intervention: Genetic and biomarker analyses
Number of subjects: 2750
Study: 26299381

Group type: EXPERIMENTAL
Intervention: Binocular indirect ophthalmoscopy (BIO) and digital retinal imaging
Number of subjects: 1257
Study: 26299414

Group type: EXPERIMENTAL
Intervention: Standard of care with prescribed medications or other therapies
Number of subjects: 262
Study: 26299436

Group type: EXPERIMENTAL
Intervention: Pain at the third month after surgery (M3)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Pain at the sixth month after surgery (M6)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of neuropathic pain (up to M6)
Number of subjects: 391
Study: 26300719

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 26300782

Group type: EXPERIMENTAL
Intervention: 2 g/day XOS for 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 29
Study: 26300790

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA for 20 minutes over the left dorsolateral prefrontal cortex
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 26300919

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid (875 mg/125 mg BID, n = 235)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Clindamycin (150 mg QID, n = 237)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid and Clindamycin
Number of subjects: 472
Study: 26300945

Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch (SHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 0
Study: 26300986

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg daily, n=87)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (n=87)
Number of subjects: 174
Study: 26300987

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Weight-loss
Number of subjects: 119
Study: 26301100

Group type: EXPERIMENTAL
Intervention: Edratide 0.5 mg
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edratide 1.0 mg
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edratide 2.5 mg
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Edratide (all doses)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 26301448

Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Risperidone discontinued
Number of subjects: 169

Group type: COMPARATOR
Intervention: Risperidone continued
Number of subjects: 169
Study: 26302380

Group type: COMPARATOR
Intervention: Expert opinion forecasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Statistical regression forecasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SIS hidden Markov model forecasting
Number of subjects: 24
Study: 26302738

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1
Study: 26303401

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study: 26304481

Group type: EXPERIMENTAL
Intervention: Dual intramuscular and intra-arterial injection of bone marrow mononuclear cells harvested from the iliac crest
Number of subjects: 49